Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Boston Scientific says that patients experienced fewer major complications with the subcutaneous implantable defibrillator compared with transvenous ICDs. Boston Scientific (NYSE:BSX) touted the results of a comparative analysis of patients treated with the subcutaneous implantable defibrillator, reporting that its lead-free ICD may be safer for patients. The lead-free S-ICD system, which uses electrodes implanted beneath the skin rather than leads connected to the heart, resulted in fewer major lead and surgical complications when compared with traditional transvenous ICDs, according to an analysis presented this week at the 2013 Europace meeting of the European Heart Rhythm Assn.
Help employers find you! Check out all the jobs and post your resume.
